Ann: Appendix 4D and Half Yearly Financial Report, page-31

AHZ are bargaining from a position of weakness (and a very low valuation base) and the track record on deals to date haven't been very good.

True, but the IP is inherently extremely valuable (especially the valve for TAVR which is longer lasting and less complications = saving money in the clinical hospital situation. You measure that value against the costs not just of the competition product but of the savings in not having repeated hospital visits, and operations in the next 10 years to quantify the value. This is HUGE IMO. There is no real competition on that.).

If you have more than one party bargaining for exclusivity, then FOMO will govern the situation dynamics. That is why it's so important to have a line of credit or some other means of remaining afloat. Easy to say now but I think the company should have put us into suspension a lot earlier, but they were probably assuming that the market would behave a lot more rationally.

The fact that we had disappointing takeup on other applications is not fatal. We have had a cliffhanger of a situation but it's far from over.

Speculative stocks are always tricky. I tend to post the opposite to the prevailing view to test it out. If you don't believe me, try another thread for size on another stock I hold. There I take the opposite view on slightly analogous facts in some ways but they're VERY different in key respects. I'm copping it in there as per usual.